AAVnerGene Inc

03/17/2026

AAVnerGene‘s partner ’ Founder & CEO, Dr. Joseph Sinkule, sat down with Professor Tim Sandle, Ph.D., CBiol, FIScT of Digital Journal to discuss how cell and could transform the treatment of motor neuron and neurodegenerative diseases.

In the Q&A, Dr. Sinkule explores the science behind the gene, the company’s focus on neuroprotection and longevity, and progress across Klotho’s lead programs, including KLTO-101 for diseases and KLTO-202 for and other neuromuscular disorders.

https://www.digitaljournal.com/tech-science/qa-harnessing-cell-and-gene-therapy-to-treat-motor-neuron-diseases/article

This link will take you to a page that’s not on LinkedIn

03/17/2026

Ultragenyx reports positive Phase 3 data for DTX301 ( )

Ultragenyx announced positive Phase 3 results from the Enh3ance trial of DTX301, an AAV8‑based gene therapy for ornithine transcarbamylase (OTC) deficiency. The study met its primary endpoint, demonstrating a statistically significant reduction in 24‑hour plasma ammonia at 36 weeks, with effects observed early and maintained over time.

Importantly, patients were able to maintain ammonia control while reducing standard therapies, and the treatment showed a favorable safety profile following a single IV AAV dose.

This is a strong late‑stage validation for systemic AAV delivery, reinforcing the role of functional potency, durability, and manufacturing consistency in advancing AAV gene therapies toward commercialization.

Read the latest press releases from Ultragenyx to follow the latest developments.

03/11/2026

A new study just showcased one of the boldest uses of AAV in neurodegeneration to date: delivering ‑engineered astrocytes across the entire brain using systemic AAV‑PHP.eB.

Why this matters？
✅ AAV‑PHP.eB enabled noninvasive, CNS‑wide delivery of CAR constructs — no direct brain injection needed.
✅ A single AAV dose programmed astrocytes to seek and clear amyloid‑β, reducing plaque burden in vivo.

This work pushes beyond gene replacement into cell‑reprogramming therapy, emerging a major leap for Alzheimer’s and CNS disease strategies.

💥 AAV isn’t just a delivery vector — it’s becoming the engine behind the next generation of precision brain therapies.

https://www.science.org/doi/10.1126/science.ads3972

03/09/2026

is BACK in the spotlight -- and Atamyo Therapeutics‘s ‑200 just dropped one of the most exciting clinical signals of 2026. Let’s hit the highlights:

⚡ AAV therapy successfully dosed in 4 children
ATA‑200 AAV gene therapy is already treating four pediatric LGMD‑R5 patients, momentum is building fast.

🛡️ AAV safety looks strong
6‑month biopsy data from the first two patients shows AAV safety confirmed so far.

📈 AAV efficacy is showing real promise
Researchers are reporting very encouraging AAV pharmacodynamic improvements, early signs the therapy is doing what it’s designed to do.

💉 One‑time, high‑dose systemic AAV infusion
ATA‑200 uses a single IV AAV dose (1.0E+14 vg/kg) to deliver the SGCG gene body‑wide.

🚀 Why This Matters
‑200 is a reminder that AAV remains one of the strongest platforms for tackling devastating genetic muscle diseases. When early AAV signals look this good, the entire field feels it.

03/09/2026

Register to attend Cell and Gene Therapies Summit from . For free!

Attendees will learn more about CGT approaches, research strategies, and regulatory trends, and understand how the patient community is shaping the future of CGTs.

The American Society of Gene & Cell Therapy is hosting Empowering Patients 2026, a Cell Therapy & Gene Therapy Summit, March 11-12. This free virtual event provides research updates and patient focused resources. Register today: asgct.org/empowering